Dr. Lincoln Chee

Senior Advisor

Career Background

  • Over 25 years of experience in healthcare as a surgeon, executive and investor
  • Parkway Pantai Limited, CEO Designate (2018-present)
  • Managing Director, Vertex Venture Management, a venture subsidiary fund of Temasek Holdings (2013-2017)
  • Technical advisor, National Research Foundation (NRF) Central Gap Fund (2017-2018)
  • Operating Partner, Advent International, a global private equity firm with more than US$ 40B AUM (2013-2014)
  • CEO and Board Member, Quality Healthcare, Hong Kong’s first publicly listed healthcare company (2003- 2012)
  • Notable past investments include Twelve (acquired by Medtronic), Arana Therapeutics (acquired by Cephalon), Biosensors International (IPO) and Phoenix Hospital Group (IPO), Quality Healthcare (acquired by BUPA International).
  • Board Experience

  • Non-Executive Board Member, Earlens Corporation (2016-2017)
  • Non-Executive Board Member, Holaira (2014-2017)
  • Non-Executive Board Member, Sensimed AG (2014-2017)
  • Non-Executive Board Member, Visterra, Inc (2014-2017)
  • Independent Non-Executive Director, Biosensors International (2009-2010)
  • Non-Executive Director, Arana Therapeutics (2006-2008)
  • Education/ Awards

  • MBBS, National University of Singapore
  • Fellow of the Royal College of Surgeons Edinburgh and a Fellow Academy of Medicine Singapore in Otorhinolaryngology Head & Neck Surgery
  • Executive Education, Business and Finance, Harvard Business School and Michigan Ross School of Business
  • Outstanding Entrepreneur of Hong Kong, Asia Pacific Entrepreneurship Awards